[
  {
    "ts": null,
    "headline": "Merck: A Pharma Giant Trading At A Decade-Low Valuation While Executing Its Post-Keytruda Playbook",
    "summary": "Merck (MRK) looks undervalued amid 2028 Keytruda patent fearsâstrong Q3 results, pipeline wins, and 12x P/E suggest upside. See more here.",
    "url": "https://finnhub.io/api/news?id=d7eb550bc47b903b546c40eb0e3f15397544c0dd79361126d70eb5032bc5a88d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767237113,
      "headline": "Merck: A Pharma Giant Trading At A Decade-Low Valuation While Executing Its Post-Keytruda Playbook",
      "id": 137955385,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merck (MRK) looks undervalued amid 2028 Keytruda patent fearsâstrong Q3 results, pipeline wins, and 12x P/E suggest upside. See more here.",
      "url": "https://finnhub.io/api/news?id=d7eb550bc47b903b546c40eb0e3f15397544c0dd79361126d70eb5032bc5a88d"
    }
  },
  {
    "ts": null,
    "headline": "Merck: Framework For Success",
    "summary": "Merck: Framework For Success",
    "url": "https://finnhub.io/api/news?id=b44cd052f91b246fcd582f25f1816f899e3e725b3bb1c5fff8247592930682b2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767236276,
      "headline": "Merck: Framework For Success",
      "id": 137955303,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=b44cd052f91b246fcd582f25f1816f899e3e725b3bb1c5fff8247592930682b2"
    }
  }
]